Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Umbilical cord-derived allogeneic mesenchymal stem cells (University of Gaziantep)
- Development stage
- Unknown
- Lead developer
- Gaziantep University
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
Umbilical cord-derived allogeneic mesenchymal stem cells (UC-MSCs) are an investigational cell therapy developed by the University of Gaziantep for the treatment of Duchenne muscular dystrophy (DMD). This therapy utilizes mesenchymal stem cells harvested from the umbilical cord, which are characterized by their low immunogenicity and high proliferative capacity. The cells are administered intravenously to both ambulatory and non-ambulatory patients. The therapeutic rationale is based on the ability of MSCs to home to sites of muscle injury and exert anti-inflammatory and immunomodulatory effects, potentially reducing the chronic inflammation and fibrosis that drive muscle degeneration in DMD. Additionally, these cells may secrete various growth factors and cytokines that support the survival and regeneration of existing muscle fibers, aiming to preserve motor function and improve the quality of life for affected individuals.
- Other names
- Umbilical Cord Based Allogenic Mesenchymal Stem CellUC-MSCs
Beyond the preview
Go deeper on Umbilical cord-derived allogeneic mesenchymal stem cells (University of Gaziantep).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Umbilical cord-derived allogeneic mesenchymal stem cells (University of Gaziantep).